Associated Genetic Biomarkers
Death domain associated protein (DAXX) is a gene that encodes a protein that functions in transcriptional repression and apoptosis. Missense mutations, nonsense mutations, silent mutations, frameshift insertions and deletions, and in-frame deletions are observed in cancers such as adrenal cancer, intestinal cancer, and stomach cancer.
DAXX is altered in 1.45% of all cancers with pancreatic neuroendocrine neoplasm, lung adenocarcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, and cutaneous melanoma having the greatest prevalence of alterations .
The most common alterations in DAXX are DAXX Mutation (1.25%), DAXX Amplification (0.17%), DAXX Frameshift (0.13%), DAXX Nonsense (0.14%), and DAXX Loss (0.04%) .
DAXX status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains DAXX status as an inclusion criterion, 1 is phase 1 (1 open).
Trials with DAXX status in the inclusion eligibility criteria most commonly target malignant solid tumor .
The most frequent alterations to serve as inclusion eligibility criteria are DAXX Deficient Expression, DAXX Frameshift, DAXX Loss, DAXX Nonsense, and DAXX c.183-c.147 Missense .
Vx-803 is the most frequent therapy in trials with DAXX as an inclusion criteria .
Significance of DAXX in Diseases
Malignant Solid Tumor +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.